FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2063375112> ?p ?o ?g. }

• W2063375112 endingPage "580" @default.
• W2063375112 startingPage "574" @default.
• W2063375112 abstract "Some prostate cancers may have molecular alterations that render them less responsive to radiation therapy; identification of these alterations before treatment might allow improved treatment optimization. This study investigated whether p53, a potential molecular determinant, could predict long-term radiation therapy outcome in a restricted group of relatively favorable-risk prostate cancer patients treated uniformly with irradiation alone.This study included 53 patients previously treated with radiotherapy for favorable-to-intermediate-risk prostate cancer. These patients were selected for relatively low pretreatment PSAs (< or =21 ng/mL) and Gleason scores (< or =7) to decrease the likelihood of nonlocalized disease, because disease localization was necessary to examine the efficacy of localized radiation therapy. The status of p53 was immunohistochemically assessed in paraffin-embedded pretreatment biopsy specimens, along with appropriate controls. This marker was selected based upon a usable mutation prevalence in early-stage prostate cancer and its potential linkage with radiation response via cell cycle, DNA repair, and cell death pathways. Correlation between p53 mutation and clinical outcome was analyzed in univariate and multivariate fashion and included conventional prognosticators, such as stage, grade, and PSA. Freedom from biochemical failure was determined using American Society for Therapeutic Radiology and Oncology criteria. Limitations of prior studies were potentially avoided by requiring adequate posttreatment follow-up (median follow-up in nonfailing patients of 5.1 years), as well as pretreatment PSA and Gleason scores that suggested localized disease, and uniformity of treatment.The total group of 53 favorable-to-intermediate-risk patients demonstrated an actuarial biochemical failure rate of 35% at 5 years. Forty percent of all specimens had a greater than 10% labeling index for p53 mutation, and actuarial biochemical control was found to strongly and independently correlate with p53 status. Patients with higher p53 labeling indices demonstrated significantly higher PSA failure rates (p < 0.001). In contrast, p53 status did not correlate with pretreatment PSA, grade, or tumor stage. Similarly, pretreatment PSA (log-rank 0.22), Gleason score (log-rank 0.93), and T stage (log-rank 0.15) were not prognostic for outcome in this group of patients selected for their relatively favorable clinical characteristics.(1) p53 status in pretreatment biopsies strongly predicted for long-term biochemical control after radiation therapy in favorable-to-intermediate-risk prostate cancer patients. (2) If validated in other independent clinical data sets, p53 status should be considered as a stratification factor in future clinical trials and could be useful in guiding treatment. Abnormal p53 status might favor surgical management, aggressive dose escalation, or p53-targeted therapy." @default.
• W2063375112 created "2016-06-24" @default.
• W2063375112 creator A5011508859 @default.
• W2063375112 creator A5036130260 @default.
• W2063375112 creator A5049728106 @default.
• W2063375112 creator A5074320591 @default.
• W2063375112 creator A5075205144 @default.
• W2063375112 date "2002-07-01" @default.
• W2063375112 modified "2023-10-18" @default.
• W2063375112 title "The role of p53 in radiation therapy outcomes for favorable-to-intermediate-risk prostate cancer" @default.
• W2063375112 cites W1903247072 @default.
• W2063375112 cites W1967434204 @default.
• W2063375112 cites W1968941811 @default.
• W2063375112 cites W1969033671 @default.
• W2063375112 cites W1974190682 @default.
• W2063375112 cites W1989007404 @default.
• W2063375112 cites W1995986482 @default.
• W2063375112 cites W1995992733 @default.
• W2063375112 cites W1999078834 @default.
• W2063375112 cites W2010917424 @default.
• W2063375112 cites W2012322426 @default.
• W2063375112 cites W2016592901 @default.
• W2063375112 cites W2018445655 @default.
• W2063375112 cites W2026743900 @default.
• W2063375112 cites W2030735294 @default.
• W2063375112 cites W2044482325 @default.
• W2063375112 cites W2045086385 @default.
• W2063375112 cites W2049102477 @default.
• W2063375112 cites W2052370054 @default.
• W2063375112 cites W2067291231 @default.
• W2063375112 cites W2070924029 @default.
• W2063375112 cites W2072489106 @default.
• W2063375112 cites W2080200822 @default.
• W2063375112 cites W2087719960 @default.
• W2063375112 cites W2089403922 @default.
• W2063375112 cites W2094315815 @default.
• W2063375112 cites W2112285253 @default.
• W2063375112 cites W2140680429 @default.
• W2063375112 cites W2147242002 @default.
• W2063375112 cites W2154055662 @default.
• W2063375112 cites W2316095838 @default.
• W2063375112 cites W2503230196 @default.
• W2063375112 cites W4294715705 @default.
• W2063375112 doi "https://doi.org/10.1016/s0360-3016(02)02781-5" @default.
• W2063375112 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12062599" @default.
• W2063375112 hasPublicationYear "2002" @default.
• W2063375112 type Work @default.
• W2063375112 sameAs 2063375112 @default.
• W2063375112 citedByCount "49" @default.
• W2063375112 countsByYear W20633751122012 @default.
• W2063375112 countsByYear W20633751122013 @default.
• W2063375112 countsByYear W20633751122014 @default.
• W2063375112 countsByYear W20633751122015 @default.
• W2063375112 countsByYear W20633751122016 @default.
• W2063375112 countsByYear W20633751122017 @default.
• W2063375112 countsByYear W20633751122021 @default.
• W2063375112 countsByYear W20633751122022 @default.
• W2063375112 countsByYear W20633751122023 @default.
• W2063375112 crossrefType "journal-article" @default.
• W2063375112 hasAuthorship W2063375112A5011508859 @default.
• W2063375112 hasAuthorship W2063375112A5036130260 @default.
• W2063375112 hasAuthorship W2063375112A5049728106 @default.
• W2063375112 hasAuthorship W2063375112A5074320591 @default.
• W2063375112 hasAuthorship W2063375112A5075205144 @default.
• W2063375112 hasConcept C121608353 @default.
• W2063375112 hasConcept C126322002 @default.
• W2063375112 hasConcept C126894567 @default.
• W2063375112 hasConcept C143998085 @default.
• W2063375112 hasConcept C144301174 @default.
• W2063375112 hasConcept C146357865 @default.
• W2063375112 hasConcept C151730666 @default.
• W2063375112 hasConcept C2775934546 @default.
• W2063375112 hasConcept C2776235491 @default.
• W2063375112 hasConcept C2779134260 @default.
• W2063375112 hasConcept C2780192828 @default.
• W2063375112 hasConcept C38180746 @default.
• W2063375112 hasConcept C509974204 @default.
• W2063375112 hasConcept C71924100 @default.
• W2063375112 hasConcept C86803240 @default.
• W2063375112 hasConceptScore W2063375112C121608353 @default.
• W2063375112 hasConceptScore W2063375112C126322002 @default.
• W2063375112 hasConceptScore W2063375112C126894567 @default.
• W2063375112 hasConceptScore W2063375112C143998085 @default.
• W2063375112 hasConceptScore W2063375112C144301174 @default.
• W2063375112 hasConceptScore W2063375112C146357865 @default.
• W2063375112 hasConceptScore W2063375112C151730666 @default.
• W2063375112 hasConceptScore W2063375112C2775934546 @default.
• W2063375112 hasConceptScore W2063375112C2776235491 @default.
• W2063375112 hasConceptScore W2063375112C2779134260 @default.
• W2063375112 hasConceptScore W2063375112C2780192828 @default.
• W2063375112 hasConceptScore W2063375112C38180746 @default.
• W2063375112 hasConceptScore W2063375112C509974204 @default.
• W2063375112 hasConceptScore W2063375112C71924100 @default.
• W2063375112 hasConceptScore W2063375112C86803240 @default.
• W2063375112 hasIssue "3" @default.
• W2063375112 hasLocation W20633751121 @default.
• W2063375112 hasLocation W20633751122 @default.
• W2063375112 hasOpenAccess W2063375112 @default.

• next